Search results
Results From The WOW.Com Content Network
Online availability of Sanofi’s half-year financial report for 2024. Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange ...
Study 3014 was a key clinical trial of approximately 24,000 patients which Sanofi-Aventis submitted to the FDA to seek approval for Ketek. The doctor who treated the most patients in Study 3014 (about 400), Maria "Anne" Kirkman Campbell, served a 57-month sentence in federal prison after pleading guilty to mail fraud, by defrauding Aventis and ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
CEO, Sanofi. Term. September 2019-. Predecessor. Olivier Brandicourt. Children. 3. Paul Hudson (born 14 October 1967) [ 2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [ 3]
The news comes months after Sanofi announced it was reviewing "separation scenarios" for the unit in a bid to focus on its core innovative drugs business. Sanofi's consumer healthcare spin-off ...
Biotech company Dendreon (NAS: DNDN) and French pharma giant Sanofi (NYS: SNY) announced layoffs earlier this week. What do these staff reductions signify for the companies and investors? Let's ...
Curia (formerly AMRI or Albany Molecular Research Inc. [ 2]) is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its ...
Across the channel, Paris-based Sanofi-Aventis announced today it agreed to develop blood-sugar monitoring systems with AgaMatrix, a privately held U.S. company. The pair will codevelop diabetes ...